SkinDermic is developing novel, safer and highly effective first-in-class drug candidates, internally discovered, for the treatment of acne and Kaposi’s Sarcoma. SkinDermic’s drug pipeline contains innovative new small molecule drugs and a peptide for the treatment of acne and Kaposi’s Sarcoma. SkinDermic’s business strategy is to partner its proprietary drug candidates.
The Company owns 5 first-in-class, internally discovered, molecules candidates for clinical development including:
- SDA-001, SDA-002 and SDA-003, anti-inflammatory molecules developed for topical use for human acne,
- SDK-001 and SDK-002, pro-apoptotic molecules for human Kaposi’s sarcoma that act selectively in HHV-8 infected cells.